Jove
Visualize
Contact Us

Related Experiment Videos

PNU-142731A Pharmacia.

G Dent1

  • 1University of Southampton School of Medicine, Division of Respiratory Cell & Molecular Biology, Centre Block-Level D, Tremona Road, Southampton, SO16 6YD, UK. Gordon_Dent@compuserve.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

Pharmacia is developing PNU-142731A, a novel asthma treatment. This compound effectively inhibits eosinophilic lung inflammation in animal models and demonstrates good bioavailability without gall bladder toxicity observed in earlier compounds.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

Letter to the Editor: Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.

The journal of prevention of Alzheimer's disease·2023
Same author

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2022
Same author

Retinal microcirculation imaging in sickle cell disease patients.

Microvascular research·2017
Same author

Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling.

Clinical and translational science·2016
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Asthma is a chronic respiratory disease characterized by airway inflammation.
  • Eosinophilic lung inflammation is a key feature of asthma, contributing to disease severity.
  • Previous drug candidates for asthma have shown limitations, including toxicity concerns.

Purpose of the Study:

  • To introduce PNU-142731A as a potential novel therapeutic agent for asthma.
  • To evaluate the efficacy of PNU-142731A in preclinical models of lung inflammation.
  • To assess the safety and pharmacokinetic profile of PNU-142731A.

Main Methods:

  • Preclinical studies in rodent models to assess inhibition of eosinophilic lung inflammation.
  • Evaluation of bioavailability and pharmacokinetic properties in animal models.
  • Comparative toxicity assessment against a previous compound (PNU-104067F).

Main Results:

  • PNU-142731A demonstrated potent inhibition of eosinophilic lung inflammation in rodents.
  • The compound exhibited a favorable bioavailability profile in animal studies.
  • PNU-142731A did not induce gall bladder toxicity, unlike the related compound PNU-104067F.

Conclusions:

  • PNU-142731A represents a promising new drug candidate for asthma treatment.
  • Its efficacy in reducing eosinophilic lung inflammation and improved safety profile warrant further clinical investigation.
  • Phase I clinical trials are underway to evaluate its therapeutic potential in humans.

Related Experiment Videos